2084-28-8

Usage

Uses

Used in Pharmaceutical Industry:
(trans-4-Carboethoxycyclohexyl)aMine Hydrochloride is used as a key intermediate in the synthesis of trans-4-(6-substituted-9-purinyl)cyclohexylcarbinols. These synthesized compounds serve as inhibitors of adenosine deaminase, an enzyme involved in the purine metabolism pathway. By inhibiting adenosine deaminase, these compounds can potentially be used in the treatment of various diseases and conditions related to purine metabolism, such as certain types of anemia and immunodeficiency disorders.
Used in Drug Synthesis:
As a cyclohexane carboxylate amino isomer, (trans-4-Carboethoxycyclohexyl)aMine Hydrochloride plays a crucial role in the development of new drugs targeting adenosine deaminase. Its unique chemical structure allows for the creation of novel compounds with potential therapeutic applications, contributing to the advancement of pharmaceutical research and drug development.

InChI:InChI=1/C9H17NO2.ClH/c1-2-12-9(11)7-3-5-8(10)6-4-7;/h7-8H,2-6,10H2,1H3;1H/t7-,8-;

Upstream product

• 1678-68-8 ethyl trans-4-aminocyclohexanecarboxylate 
• 64-17-5 ethanol 
• 3685-23-2 cis-4-aminocyclohexane-1-carboxylic acid 
• 94-09-7 p-aminoethylbenzoate 
• 51498-33-0 ethyl 4-amino-1-cyclohexanecarboxylate 
• 19145-96-1 diethyl cyclohexane-trans-1,4-dicarboxylate 
• 619-82-9 trans-hexahydroterephthalic acid 
• 27960-59-4 trans-4-aminocyclohexanecarboxylic acid hydrochloric acid 
• 1776-53-0 trans-4-aminocyclohexanecarboxylic acid 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES

The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Trans -4 - amino - cyclohexyl carboxylic acid ethyl ester hydrochloride of preparation method (by machine translation)

The invention discloses a method for trans - 4 - amino - cyclohexyl carboxylic acid ethyl ester hydrochloride of the preparation method, which belongs to the field of organic chemistry, the method is to trans - 1, 4 - cyclohexyl dicarboxylic acid as a sta

METHOD FOR PRODUCING DICARBOXYLIC ACID COMPOUND

It is an object of the present invention to provide an excellent method for producing an excellent therapeutic agent. The solution of the present invention is as shown in the following scheme: wherein R1 represents a C1-C6 alkyl group, R2 represents a C1-C6 alkyl group, and R3 represents a C1-C6 alkyl group.

TETRACYCLIC CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS

New pyridin-2(1H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES

Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Aminopurine Compounds having the following structure: (I) wherein R1 , R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

METHOD FOR PRODUCING ALKYL TRANS-4-AMINOCYCLOHEXANECARBOXYLATE HYDROCHLORIDE

PROBLEM TO BE SOLVED: To provide a method for industrially advantageously producing a high-purity alkyl trans-4-aminocyclohexanecarboxylate hydrochloride. SOLUTION: Alkyl 4-aminocyclohexanecarboxylates in (50/50) to (0/100) cis/trans isomer ratio are reacted with an amine hydrochloride in a 1-10C aliphatic alcohol and crystallization is then carried out. Thereby, the alkyl trans-4-aminocyclohexanecarboxylate hydrochloride is produced.